NASDAQ$KIDS
OrthoPediatrics Corp · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
OrthoPediatrics' Q4 2021 performance showed revenue growth and strategic progress.
OrthoPediatrics Corp. reported a 31% increase in revenue for the fourth quarter of 2021, reaching $24.8 million compared to $18.9 million in the same period last year. The growth was primarily driven by strong performance in trauma and deformity, with international revenue showing a significant increase. The company also issued full year 2022 revenue guidance of $118 million to $121 million and expects positive adjusted EBITDA for the full year 2022.
- Helped an estimated 9,500 children in Q4 2021 and a record 38,000 for the full year, bringing the total to over 234,000 since inception.
- Total revenue for Q4 2021 was $24.8 million, a 31% increase year-over-year, with domestic revenue up 11% and international revenue up 363%.
- Record total annual revenue for 2021 reached $98.0 million, a 38% increase year-over-year, with domestic revenue up 24% and international revenue up 150%.
- Adjusted EBITDA loss for full year 2021 improved by $5.7 million compared to 2020.
Headline financials
Revenue & EPS history
OrthoPediatrics · Revenue · Quarterly
$24.8M
Revenue by segment
OrthoPediatrics · $24.8M total across 3 segments · Q4 2021
- Trauma and Deformity$16.5M+46.5%66.6%
- Scoliosis$7.17M+8.1%28.9%
- Sports Medicine/Other$1.11M+10.3%4.5%
Forward guidance
OrthoPediatrics expects total 2022 revenue of approximately $118 million to $121 million and to generate several million dollars of positive adjusted EBITDA for the full year 2022.
Tailwinds
- Company expects total 2022 revenue of approximately $118 million to $121 million dollars, representing growth of 20% to 23% compared to full year 2021.
- The Company also expects to generate several million dollars of positive adjusted EBITDA for the full year 2022.
Headwinds
- The Company remains cognizant of the unique external operating environment due to COVID-19 and its impact on elective procedures.
- COVID-19 may impact healthcare infrastructure and staffing levels.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-0.6%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.4%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+13.1%
Q2 2022
Best reaction
-13.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | +13.7% | +14.0% | |
| Q4 2025 | +8.3% | +3.9% | -12.8% | |
| Q3 2025 | -2.6% | -3.0% | +9.3% | |
| Q1 2025 | +4.0% | +4.6% | -4.5% | |
| Q4 2024 | +11.9% | +7.0% | -0.8% | |
| Q3 2024 | -7.8% | -16.2% | -22.3% | |
| Q2 2024 | -7.8% | -9.0% | +3.8% | |
| Q1 2024 | +5.7% | -5.3% | -1.9% | |
| Q4 2023 | +5.4% | +1.9% | +0.8% | |
| Q3 2023 | +4.2% | -5.1% | +8.9% | |
| Q2 2023 | -4.6% | -4.9% | -7.2% | |
| Q1 2023 | -7.5% | -8.0% | -14.4% | |
| Q4 2022 | +0.5% | +1.7% | -0.8% | |
| Q3 2022 | -13.0% | -12.4% | +0.8% | |
| Q2 2022 | +13.1% | +19.2% | -0.8% | |
| Q1 2022 | -10.2% | -17.7% | -8.1% | |
| Q4 2021 | -5.8% | -6.3% | -2.0% | |
| Q3 2021 | +2.0% | +0.4% | -19.4% | |
| Q2 2021 | +6.9% | +4.5% | +9.2% | |
| Q1 2021 | +10.1% | +4.4% | +4.4% | |
| Q4 2020 | -7.1% | -8.6% | +2.3% | |
| Q3 2020 | -6.5% | +6.5% | -2.1% | |
| Q2 2020 | +4.7% | +9.7% | -0.6% | |
| Q1 2020 | +2.8% | +4.8% | +10.0% | |
| Q4 2019 | +1.1% | -4.5% | -19.5% | |
| Q3 2019 | +5.7% | +8.9% | +10.6% | |
| Q2 2019 | -0.2% | -1.0% | +10.9% | |
| Q1 2019 | -9.5% | -10.3% | -8.3% | |
| Q4 2018 | -4.3% | -2.0% | -6.2% | |
| Q3 2018 | -12.5% | -16.0% | -11.4% | |
| Q2 2018 | +2.7% | +2.7% | +23.7% | |
| Q1 2018 | -1.1% | +1.9% | +32.0% | |
| Q4 2017 | -1.9% | +3.4% | -2.9% | |
| Q3 2017 | -11.3% | -2.0% | -8.5% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro